SKYE · Skye Bioscience, Inc.

Summary

Skye Bioscience, Inc. received a Nasdaq deficiency letter on March 17, 2026, notifying that its common stock's closing bid price was below $1.00 per share for 30 consecutive business days, violating Rule 5450(a)(1). The company has 180 calendar days until September 14, 2026, to regain compliance, with trading continuing uninterrupted on The Nasdaq Global Market under 'SKYE', though no assurance of success.

Key takeaways

• Received Nasdaq deficiency letter on March 17, 2026, for bid price below $1.00 for 30 consecutive business days under Rule 5450(a)(1)
• 180 calendar days until September 14, 2026, to regain compliance
• Compliance possible if bid price closes at $1.00 or more for 10 consecutive business days
• Reverse stock split must be completed no later than ten business days prior to September 14, 2026
• Potential second 180-day period if meets Nasdaq Capital Market standards except bid price
• No immediate effect on listing; common stock continues trading as 'SKYE'